Malignant Melanoma (Acral Lentiginous)

Comprehensive Clinical Guide: Acral Lentiginous Melanoma (ALM)

1. Introduction and Overview

Acral Lentiginous Melanoma (ALM) represents a distinct and aggressive subtype of cutaneous melanoma. Unlike more common forms of melanoma that are primarily associated with cumulative ultraviolet (UV) radiation exposure, ALM arises on the "acral" surfaces—the non-hair-bearing skin of the palms, soles, and the subungual (under the nail) regions.

While ALM accounts for a relatively small percentage of total melanoma diagnoses in Caucasian populations (approximately 2–5%), it is the most common subtype of melanoma seen in individuals with darker skin pigmentation (Fitzpatrick skin types IV–VI), including those of African, Asian, and Hispanic descent. Due to its location, ALM is frequently overlooked by patients and clinicians alike, leading to delayed diagnosis and, consequently, a higher rate of advanced-stage presentation compared to other cutaneous melanomas.

2. Etiology and Pathophysiology

The underlying pathogenesis of ALM remains a subject of intense oncological research. Unlike superficial spreading melanoma, ALM is not strongly correlated with chronic sun exposure or history of severe blistering sunburns.

The Genetic Landscape

ALM is characterized by a unique genomic profile that differentiates it from UV-induced melanomas:
* BRAF Mutations: These are significantly less common in ALM compared to non-acral melanomas.
* KIT Mutations/Amplifications: A hallmark of ALM, particularly in mucosal and acral sites. KIT-targeted therapies have become a clinical consideration in advanced cases.
* Copy Number Variations (CNVs): ALM exhibits a high degree of chromosomal instability, characterized by frequent gains and losses of genetic material, which contributes to its aggressive biological behavior.
* Cyclin D1 Amplifications: Often observed, potentially driving the rapid proliferation of malignant melanocytes.

Mechanistic Development

The transformation of melanocytes in the basal layer of the epidermis into malignant cells in ALM typically follows a vertical growth phase that is often preceded by a long radial growth phase. The "lentiginous" component refers to the proliferation of atypical melanocytes along the dermo-epidermal junction, which eventually invades the deeper dermis.

3. Clinical Presentation and Diagnostic Criteria

Early detection is the single most important prognostic factor for ALM. Clinical suspicion must be high for any pigmented lesion appearing on the palms, soles, or nail apparatus.

The "ABCDEF" Rule for Acral Melanoma

Because the standard ABCDE criteria for melanoma are often insufficient for acral sites, the modified "ABCDEF" rule is employed:
* A (Age): Patients of dark-skinned ethnicity or older age.
* B (Band): A band of brown/black pigmentation in the nail (melanonychia).
* C (Color): Color variation, especially with variegated shades of brown, black, or blue.
* D (Diameter): Lesions greater than 6mm or rapid growth.
* E (Extension): Hutchinson’s sign—the extension of pigment onto the periungual skin (nail fold).
* F (Finger/Foot): Any new or changing lesion on the digits or plantar surfaces.

Differential Diagnosis

Clinicians must distinguish ALM from several benign conditions to prevent unnecessary procedures while ensuring malignancy is not missed:
| Condition | Distinguishing Feature |
| :--- | :--- |
| Subungual Hematoma | History of trauma; grows out with nail plate; typically red/purple. |
| Acral Nevus | Stable, symmetrical, uniform color patterns. |
| Fungal Infection | Often involves the nail plate texture; lacks pigment migration to skin. |
| Pyogenic Granuloma | Rapidly bleeding, vascular, usually lacks pigment. |
| Warts (Verruca) | Surface disruption, lacks pigmentation patterns. |

4. Clinical Staging and Prognosis

Staging for ALM follows the American Joint Committee on Cancer (AJCC) TNM system, which evaluates Tumor thickness (Breslow depth), Nodal involvement, and Metastasis.

The Role of Breslow Depth

Breslow depth is the measurement (in millimeters) from the top of the granular layer of the epidermis to the deepest point of tumor invasion.
* < 1.0 mm: Early stage, excellent 5-year survival.
* 1.0 – 2.0 mm: Intermediate risk.
* > 2.0 mm: High risk, significant potential for lymphatic spread.

Prognostic Factors

• Ulceration: Presence of ulceration is a powerful independent predictor of poor prognosis.
• Mitotic Rate: High mitotic activity indicates aggressive cellular division.
• Lymph Node Status: The most significant prognostic indicator of survival; sentinel lymph node biopsy (SLNB) is standard for lesions >0.8mm or those with ulceration.

5. Standard Diagnostic Procedures

When ALM is suspected, a systematic diagnostic approach is mandatory.

Dermoscopy (The Gold Standard)

Dermoscopy allows for the visualization of sub-surface structures that are invisible to the naked eye. Key patterns in ALM include:
* Parallel Ridge Pattern: A highly specific indicator for acral melanoma, where pigment follows the ridges of the skin markings.
* Asymmetric Pigmentation: Irregular, non-homogeneous distribution of colors.
* Blue-White Veil: Suggests deep dermal invasion.

Biopsy Techniques

• Excisional Biopsy: The gold standard. The entire lesion is removed with a 2–3mm margin.
• Punch Biopsy: Used for large lesions where excision is not immediately feasible, though it carries a risk of sampling error.
• Nail Matrix Biopsy: Required for subungual lesions; often involves specialized orthopedic/dermatologic surgical techniques to avoid nail deformity.

6. Management and Treatment Protocols

Treatment is multidisciplinary, involving dermatologists, surgical oncologists, and medical oncologists.

Surgical Management

1. Wide Local Excision (WLE): Removal of the primary tumor with margins determined by the Breslow depth (typically 1–2 cm).
2. Sentinel Lymph Node Biopsy (SLNB): Recommended for patients with intermediate-to-thick tumors to assess for occult nodal metastasis.
3. Amputation: Historically common for subungual melanoma, though current trends favor "digit-sparing" surgery when margins can be cleared effectively.

Systemic Therapy

For advanced, unresectable, or metastatic ALM:
* Immunotherapy: Checkpoint inhibitors (Anti-PD-1 like Pembrolizumab or Nivolumab; Anti-CTLA-4 like Ipilimumab) are now first-line treatments.
* Targeted Therapy: If a KIT mutation is confirmed, Tyrosine Kinase Inhibitors (TKIs) like Imatinib may be utilized.

7. Risks, Side Effects, and Contraindications

• Surgical Morbidity: Wide excision on the foot can lead to wound healing complications, infection, and chronic pain, impacting gait.
• Immunotherapy Risks: Immune-related adverse events (irAEs) include colitis, pneumonitis, hepatitis, and endocrinopathies.
• Contraindications: Systemic therapy may be contraindicated in patients with severe autoimmune disease or those who are organ transplant recipients due to the risk of rejection.

8. Massive FAQ Section

1. Is ALM caused by sun exposure?
No. Unlike most melanomas, ALM is not linked to UV exposure. Its exact cause is currently unknown, though genetic factors play a significant role.

2. Can ALM occur in people with light skin?
Yes, though it is rarer. It is important for everyone, regardless of skin tone, to monitor the palms and soles.

3. What is the "Hutchinson’s Sign"?
It is the spread of pigment from the nail bed onto the surrounding cuticle or nail fold. It is a critical warning sign of subungual melanoma.

4. If I have a dark streak in my nail, do I have cancer?
Not necessarily. It could be a subungual hematoma or a benign nail matrix nevus. However, any new or changing streak must be evaluated by a dermatologist immediately.

5. How often should I check my feet?
Self-examination should occur monthly. Use a mirror to inspect the soles of your feet and between the toes.

6. Does ALM spread quickly?
Because it is often diagnosed at a later stage, it may appear to spread quickly. Early-stage ALM is highly treatable, but advanced ALM is biologically aggressive.

7. Is a biopsy painful?
Local anesthesia is used. While there is minor discomfort, the procedure is generally well-tolerated.

8. What is the role of genetics in ALM?
Research suggests that specific mutations in the KIT gene are more common in ALM, which helps doctors select targeted therapies.

9. Can ALM recur?
Yes, local recurrence is possible if margins were insufficient. Systemic recurrence is also a risk, which is why long-term surveillance is necessary.

10. Why is ALM harder to diagnose?
It occurs in areas that are frequently ignored during routine body checks, and it often mimics benign conditions like plantar warts or fungal infections.

9. Conclusion

Acral Lentiginous Melanoma is a clinical challenge that demands a high index of suspicion. By understanding the unique genetic drivers, the importance of dermatoscopic evaluation, and the necessity of early surgical intervention, clinicians can significantly improve patient outcomes. Education remains the primary tool in the fight against ALM; patients must be empowered to recognize the subtle changes in their extremities that could signal this life-altering diagnosis.

Disclaimer: This guide is for educational purposes only and does not constitute formal medical advice. Always consult with a board-certified dermatologist or oncologist for personal health concerns or diagnostic procedures.